Dry Eye Disease Clinical Trial
Official title:
The Utility of in Vivo Confocal Microscopy (IVCM) to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease (DED)
Verified date | February 2022 |
Source | Tufts Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This research study is looking to see if in vivo confocal microscopy (IVCM) imaging can be used to confirm clinical findings (which are noted by the doctor during an eye exam) and measure the immune response to the inflammation in the subject's cornea (the front part of the eyeball). Additionally, this study is trying to determine the effectiveness of two eye-drops, Lotemax and artificial tears, in treating the inflammation associated with DED by measuring changes in immune cells with IVCM imaging. The subject will be treated with either Lotemax (loteprednol) or artificial tears (a lubricating eye drop with no medication). Lotemax is an FDA-approved steroid eye-drop that is often used to treat inflammation associated with DED. Artificial tears are approved by the FDA for treatment of dryness associated with DED. Thus, this study is designed to determine the effects of the administration of a topical steroid, Lotemax, over a treatment period of 6 weeks, using novel methods of detecting efficacy. In order to achieve the aforementioned goal, subjects will be prospectively randomized to one of two treatment arms - Lotemax or artificial tear. Both groups will follow the same study schedule.
Status | Completed |
Enrollment | 38 |
Est. completion date | January 28, 2018 |
Est. primary completion date | April 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 89 Years |
Eligibility | Inclusion Criteria: - Age 18-89 years. - Willing and able to provide written informed consent. - Willing and able to comply with study assessments for the full duration of the study. - In good stable overall health. - Corneal dendritiform cell count by confocal microscopy of >=75/mm2 (13 immune cells per image) - Diagnosis of dry eye disease based on the followings: - Symptoms of dry eye disease such as foreign body sensation, burning, stinging, light sensitivity for at least 6 months. - Two or more of the following objective signs: - Schirmer test with anesthesia <10 mm at 5 minutes [mean Schirmer between eyes. - Tear break-up time (TBUT) of <10 seconds. - Corneal fluorescein staining of 4 (NEI grading scheme, 0-15) in at least one eye - Lissamine green staining of the nasal and temporal conjunctiva (NEI grading scheme, 0-18) in at least one eye Exclusion Criteria: - Central corneal subbasal dendritic cell count by in vivo confocal microscopy of <75/mm2 in both eyes - Active ocular allergies - Active allergies to steroids, aminoglycosides, or benzalkonium chloride (BAK) - History of contact lens wear within 3 months before enrollment. - Intraocular surgery or ocular laser surgery within 3 months before enrollment. - History of ocular infection within 3 months before enrollment. - History of topical (for ophthalmic use) or systemic steroid treatment (Loteprednol (other than Lotemax suspension used in our study), Difluprednate, Fluorometholone, Prednisolone, Dexamethasone, Triamcinolone, Rimexolone, Medrysone) within 1 month before enrollment. In case of topical ophthalmic steroid use, a wash-out period of 1 month is required. - History of increased intraocular pressure after using topical steroids (steroid responsive) - Change in systemic immunosuppression medication in the past 3 months. - History of any change in the frequency of topical cyclosporine or oral tetracycline compounds (tetracycline, doxycycline, and minocycline) within 1 month before enrollment. - Any condition (including language barrier) that precludes subject's ability to comply with study requirements including completion of study. |
Country | Name | City | State |
---|---|---|---|
United States | Tufts Medical Center | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Tufts Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | IVCM for Density of Corneal Immune Dendritiform Cells | Density (in cells/mm2) of Corneal Immune Dendritiform Cells | 2 Weeks | |
Primary | IVCM for Density of Corneal Immune Dendritiform Cells | Density (in cells/mm2) of corneal immune dendritiform cells | 6 Weeks | |
Primary | IVCM for Corneal Immune Dendritiform Cell (DC) Morphology | Morphology (in cells/mm2) of Corneal Immune Dendritiform Cells | 2 Weeks | |
Primary | IVCM for Corneal Immune Dendritiform Cell (DC) Morphology | Morphology (in cells.mm2) of Corneal Immune Dendritiform Cells | 6 Weeks | |
Secondary | Ocular Signs: Corneal Epitheliopathy | Corneal Fluorescein Staining Using the National Eye Institute (NEI) Grading Scheme Minimum score-0 Maximum score-15 Higher score means worse outcome | 2 Weeks | |
Secondary | Ocular Signs: Corneal Epitheliopathy | Corneal Fluorescein Staining Using the National Eye Institute (NEI) Grading Scheme Minimum score-0 Maximum score-15 Higher score means worse outcome | 6 Weeks | |
Secondary | Ocular Signs: Conjunctival Epitheliopathy | Conjunctival Lissamine Green Staining Using National Eye Institute (NEI) Grading Scheme Minimum score-0 Maximum score-18 Higher score means worse outcome | 2 Weeks | |
Secondary | Ocular Signs: Conjunctival Epitheliopathy | Conjunctival Lissamine Green Staining Using National Eye Institute (NEI) Grading Scheme Minimum score-0 Maximum score-18 Higher score means worse outcome | 6 Weeks | |
Secondary | Ocular Symptoms: Ocular Surface Disease Index (OSDI) Questionnaire | Total Score of the Ocular Surface Disease Index (OSDI) Questionnaire Minimum score- 0 Maximum score-100 Higher score means worse outcome | 2 Weeks | |
Secondary | Ocular Symptoms: Ocular Surface Disease Index (OSDI) Questionnaire | Total Score of the Ocular Surface Disease Index (OSDI) Questionnaire Minimum score- 0 Maximum score-100 Higher score means worse outcome | 6 Weeks | |
Secondary | Ocular Signs: Intraocular Pressure (IOP) by Measure of Applanation Tonometry | Intraocular Pressure (IOP) will be measured via Applanation and the result will have these units: mmHg | 2 Weeks | |
Secondary | Ocular Signs: Intraocular Pressure (IOP) by Measure of Applanation Tonometry | Intraocular Pressure (IOP) will be measured via Applanation and the result will have these units: mmHg | 6 Weeks | |
Secondary | Ocular Signs: Tear Break Up Time (TBUT) | Tear Break Up Time (TBUT) will be recorded in seconds | 2 Weeks | |
Secondary | Ocular Signs: Tear Break Up Time (TBUT) | Tear Break Up Time (TBUT) will be recorded in seconds | 6 Weeks | |
Secondary | Ocular Signs: Schirmer's Test With Anesthesia | The Schirmer's Test (performed using Anesthesia) will be measured in mm. | 2 Weeks | |
Secondary | Ocular Signs: Schirmer's Test With Anesthesia | The Schirmer's Test (performed using Anesthesia) will be measured in mm. | 6 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03216096 -
Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease
|
Phase 1 | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT04656197 -
The Ocular Microbiome in Patients With Dry Eye Disease
|
||
Completed |
NCT05031806 -
Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease
|
Phase 1 | |
Completed |
NCT03688802 -
Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation
|
Phase 2 | |
Completed |
NCT05213156 -
Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease
|
Phase 4 | |
Completed |
NCT04548427 -
Study to Evaluate the Efficacy and Safety of CKD-352
|
Phase 3 | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT02254265 -
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
|
Phase 2/Phase 3 | |
Completed |
NCT00395759 -
The Visual Effect of an Investigational Artificial Tear in the Tear Layer.
|
N/A | |
Completed |
NCT00680108 -
A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution
|
Phase 2 | |
Recruiting |
NCT06064071 -
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
|
N/A | |
Completed |
NCT04139122 -
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06375343 -
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
|
Phase 1 | |
Completed |
NCT01468168 -
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
|
Phase 2 | |
Completed |
NCT01014078 -
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease
|
Phase 4 | |
Completed |
NCT00799682 -
Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®
|
Phase 4 | |
Completed |
NCT05082974 -
Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)
|
Phase 3 | |
Recruiting |
NCT06146881 -
Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia
|
Phase 2 | |
Completed |
NCT03292809 -
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
|
Phase 2/Phase 3 |